- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07603167
p-PHOTOLARYNX- ANTHEM: Photon-Counting CT in Laryngeal Cancer Staging (H&NRAD-2025-01)
p-PHOTOLARYNX- ANTHEM: Pilot Photon-Counting CT Evaluation of the Paraglottic Space and Cartilage Involvement in Laryngeal Cancer
Laryngeal cancer can affect speaking, swallowing, and breathing. Treatment selection depends on accurately defining tumor spread within the larynx, particularly invasion of the paraglottic space, thyroid cartilage, and subglottic region. Understaging may lead to insufficient treatment and recurrence, whereas overstaging may result in unnecessarily aggressive surgery and impaired quality of life.
CT and MRI are routinely used for local staging, but both have limitations. Conventional CT may have limited soft-tissue and cartilage contrast, while MRI is more time-consuming, motion-sensitive, and not feasible in all patients. Photon-counting CT (PCCT) is a new CT technology offering higher spatial resolution, improved tissue contrast, and reconstructions at different energy levels.
This study evaluates whether PCCT performed during phonation, while the patient produces a sustained sound, can improve local staging of laryngeal cancer. Phonation may better separate and display laryngeal structures, improving detection of tumor extension.
The main hypothesis is that optimized phonation PCCT reconstructions can assess tumor spread more accurately than standard CT and may approach MRI performance. Participants undergo PCCT as part of routine preoperative imaging. Images are reconstructed using different settings and reviewed by radiologists for image quality and tumor extension. When surgery is performed, imaging findings are compared with surgical and histopathological results.
The study aims to identify the most accurate PCCT reconstruction strategy to support better treatment planning in laryngeal cancer.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a prospective, single-center observational imaging study designed to evaluate the diagnostic performance of photon-counting computed tomography (PCCT) acquired during phonation for local staging of biopsy-proven laryngeal squamous cell carcinoma.
Study Overview and Imaging Workflow
Eligible adult patients with histologically confirmed laryngeal squamous cell carcinoma referred for preoperative imaging undergo contrast-enhanced PCCT as part of routine clinical work-up. PCCT examinations are performed on a dedicated photon-counting CT system using a standardized acquisition protocol optimized for ultra-high-resolution imaging of the larynx during phonation. Imaging is acquired in the venous phase under sustained vocalization to enhance functional and morphological assessment of glottic and subglottic structures.
For each acquisition, multiple reconstructions are generated, including ultra-high-resolution virtual monoenergetic images (VMIs) at predefined energy levels and different reconstruction kernels. A 70-keV reconstruction with standard slice thickness is included as an energy-integrating detector (EID)-CT-like reference. When available, previously acquired conventional CT and/or MRI performed as part of standard care are included for comparative analysis. Surgical histopathology serves as the reference standard for local tumor extension.
Qualitative Image Assessment
Qualitative analysis is restricted to phonation acquisitions to maximize clinical relevance and reduce reader burden. Four expert head and neck radiologists independently review anonymized and randomized datasets, blinded to reconstruction parameters. For each dataset, readers assign a qualitative diagnostic quality score using a five-point Likert scale and evaluate tumor extension into the paraglottic space, thyroid cartilage (with distinction between inner cortical erosion and full-thickness invasion), and subglottic space using predefined ordinal scoring systems. Multiplanar reformations aligned with the glottic plane and axis are mandatorily assessed as part of each dataset.
Quantitative Image Assessment
Quantitative analysis is performed by two independent observers on a dedicated workstation. Standardized regions of interest (ROIs) are placed in the primary tumor, adjacent non-tumoral laryngeal tissues, subcutaneous fat (for noise estimation), and the common carotid artery (vascular reference). ROIs are defined on a representative axial slice and propagated across all reconstructions to ensure measurement consistency. Quantitative metrics include attenuation values, image noise, signal-to-noise ratio (SNR), and contrast-to-noise ratio (CNR).
Data Management and Quality Assurance
Data are collected using structured electronic case report forms (eCRFs) derived from hospital source documents. All imaging data are anonymized prior to analysis. Quality assurance procedures are based on written standard operating procedures at the sponsor site and include verification of data completeness, internal consistency checks, and cross-validation of imaging assessments with source data (radiology reports, surgical and pathology records). Access to source data is permitted for authorized personnel in accordance with Good Clinical Practice and data protection regulations.
Statistical Analysis Plan
Given the exploratory, pilot nature of the study, the planned sample size of 60 patients is based on feasibility and the need to support descriptive and comparative multi-dataset, multi-reader analyses rather than formal hypothesis testing. Quantitative variables are summarized using appropriate descriptive statistics based on data distribution. Interobserver agreement is assessed using intraclass correlation coefficients for quantitative measures and Fleiss' kappa for ordinal qualitative scores.
The effects of VMI energy level and reconstruction kernel on quantitative and qualitative outcomes are evaluated using mixed-effects models accounting for repeated measures within patients and readers. Diagnostic performance of PCCT, and where available conventional CT and MRI, is assessed using sensitivity, specificity, predictive values, and receiver operating characteristic analysis with histopathology as the reference standard. Adjustment for multiple comparisons is applied when appropriate.
Handling of Missing Data
Missing or non-evaluable data (e.g., due to severe artifacts or unavailable histopathology) are documented explicitly. Analyses are primarily conducted on available data without imputation, and sensitivity analyses may be performed to assess the impact of missing values.
Ethical and Operational Considerations
The study does not modify standard clinical management. No study-specific adverse events are anticipated. All procedures comply with the Declaration of Helsinki, Good Clinical Practice, and applicable regulatory requirements. Written informed consent is obtained prior to participation.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Luoghi di studio
-
-
-
Rozzano, Italia, 20089
- HUMANITAS Research Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
1. SELECTION CRITERIA
Inclusion Criteria
- Adults (≥18 years)
- Biopsy-proven laryngeal cancer squamous cell carcinoma
- Candidate for surgical staging able to undergo PCCT
Exclusion criteria
- Renal failure
- Allergy to contrast medium
- Refusal of informed consent
- Lack of histopathologic confirmation
- Histopathologic diagnosis of non laryngeal tumors
- Poor image quality due to severe artifacts
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Biopsy-Proven Laryngeal Squamous Cell Carcinoma Patients
A total of sixty patients, with biopsy-proven and clinical laryngeal squamous cell carcinoma
|
Photon-Counting CT (PCCT) will be performed using the Siemens Healthineers NAEOTOM Alpha, the latest generation of CT technology and the first system to apply photon-counting detector technology to laryngeal imaging.
Its CdTe detectors count individual photons and measure their energy, enabling true spectral imaging with ultra-high spatial resolution (voxel size down to 0.2 mm).
Multi-energy maps significantly improve tissue differentiation, allowing clearer distinction between paraglottic fat, non-ossified thyroid cartilage, and tumor tissue.
The technology also reduces artifacts and enhances contrast, enabling detailed evaluation of the laryngeal cartilages and paraglottic space.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Diagnostic Accuracy of Phonation Photon-Counting CT (PCCT) for Local Tumor Extension
Lasso di tempo: From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
|
Description: To evaluate the diagnostic accuracy of phonation PCCT in identifying paraglottic space invasion, thyroid cartilage invasion (including distinction between inner cortical erosion and full-thickness invasion), and subglottic extension, using surgical and histopathological findings as the reference standard. |
From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
|
|
Identification of the Optimal PCCT Reconstruction for Local Staging
Lasso di tempo: From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
|
To identify the best-performing phonation PCCT reconstruction (defined by VMI energy level and reconstruction kernel) for each anatomical target (paraglottic space, thyroid cartilage, subglottic space), based on diagnostic accuracy relative to histopathology.
|
From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Robustness of Local Staging Across PCCT Reconstructions
Lasso di tempo: From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
|
To assess variability in local staging classification (paraglottic space invasion, cartilage involvement, subglottic extension) across different phonation PCCT reconstructions, including staging upgrades or downgrades between datasets.
|
From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
|
|
Interobserver Agreement for Qualitative and Staging Assessments
Lasso di tempo: From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
|
To evaluate interobserver reproducibility among readers for qualitative diagnostic quality scores and ordinal staging assessments of paraglottic space invasion, cartilage involvement, and subglottic extension. . |
From completion of baseline phonation PCCT imaging to histopathological correlation, assessed up to 12 weeks.
|
|
Tumor attenuation
Lasso di tempo: At baseline imaging, before surgery.
|
Mean attenuation measured in Hounsfield Units (HU) within tumor regions of interest.
|
At baseline imaging, before surgery.
|
|
Image noise
Lasso di tempo: At baseline imaging, before surgery.
|
Image noise defined as the standard deviation of attenuation measured in a homogeneous region (e.g., subcutaneous fat).
|
At baseline imaging, before surgery.
|
|
Signal-to-noise ratio (SNR)
Lasso di tempo: At baseline imaging, before surgery.
|
Signal-to-noise ratio calculated as mean tumor attenuation divided by image noise.
|
At baseline imaging, before surgery.
|
|
Contrast-to-noise ratio (CNR)
Lasso di tempo: At baseline imaging, before surgery.
|
Contrast-to-noise ratio calculated as the difference in attenuation between tumor and reference tissue divided by image noise.
|
At baseline imaging, before surgery.
|
|
CT dose index volume (CTDIvol)
Lasso di tempo: At baseline imaging, before surgery.
|
Volume CT dose index measured in milligray (mGy)
|
At baseline imaging, before surgery.
|
|
Dose-length product (DLP)
Lasso di tempo: At baseline imaging, before surgery.
|
Dose-length product measured in milligray-centimeters (mGy·cm).
|
At baseline imaging, before surgery.
|
|
Effective dose
Lasso di tempo: At baseline imaging, before surgery.
|
Estimated effective radiation dose expressed in millisieverts (mSv).
|
At baseline imaging, before surgery.
|
|
Comparison of PCCT with Conventional CT and MRI
Lasso di tempo: From completion of phonation PCCT imaging to completion of multimodality image review and histopathological correlation, assessed up to 12 weeks.
|
To compare the diagnostic performance of phonation PCCT with conventional energy-integrating detector CT and MRI, when available, using histopathology as the reference standard.
|
From completion of phonation PCCT imaging to completion of multimodality image review and histopathological correlation, assessed up to 12 weeks.
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Kuno H, Sakamaki K, Fujii S, Sekiya K, Otani K, Hayashi R, Yamanaka T, Sakai O, Kusumoto M. Comparison of MR Imaging and Dual-Energy CT for the Evaluation of Cartilage Invasion by Laryngeal and Hypopharyngeal Squamous Cell Carcinoma. AJNR Am J Neuroradiol. 2018 Mar;39(3):524-531. doi: 10.3174/ajnr.A5530. Epub 2018 Jan 25.
- Preda L, Conte G, Bonello L, Giannitto C, Tagliabue E, Raimondi S, Ansarin M, De Benedetto L, Cattaneo A, Maffini F, Bellomi M. Diagnostic accuracy of surface coil MRI in assessing cartilaginous invasion in laryngeal tumours: Do we need contrast-agent administration? Eur Radiol. 2017 Nov;27(11):4690-4698. doi: 10.1007/s00330-017-4840-x. Epub 2017 May 5.
- Becker M, Zbaren P, Casselman JW, Kohler R, Dulguerov P, Becker CD. Neoplastic invasion of laryngeal cartilage: reassessment of criteria for diagnosis at MR imaging. Radiology. 2008 Nov;249(2):551-9. doi: 10.1148/radiol.2492072183.
- Yu Z, Leng S, Kappler S, Hahn K, Li Z, Halaweish AF, Henning A, McCollough CH. Noise performance of low-dose CT: comparison between an energy integrating detector and a photon counting detector using a whole-body research photon counting CT scanner. J Med Imaging (Bellingham). 2016 Oct;3(4):043503. doi: 10.1117/1.JMI.3.4.043503. Epub 2016 Dec 14.
- Becker M, Zbären P, Casselman JW, et al. MRI in the Preoperative Staging of Laryngeal Cancer. AJNR. 2010;31(4):592-599. doi:10.3174/ajnr.A1912
- Castelijns JA, van den Brekel MW. Imaging of Laryngeal Cancer. Eur J Radiol. 2008;66(3):501-517. doi:10.1016/j.ejrad.2008.01.046
- Leng S, Bruesewitz M, Tao S, et al. Photon-Counting CT: Impact on Noise, Spatial Resolution, and Image Quality. Radiology. 2020;297(3):738-746. doi:10.1148/radiol.2020201407
- Li H, Yadava G, Procopiou M, et al. Photon-Counting Detector CT: Clinical Applications of an Emerging Technology. Radiographics. 2022;42(5):1439-1456. doi:10.1148/rg.220014
- Hermans R, Boomgaert L, Cockmartin L, Binst J, De Stefanis R, Bosmans H. Photon-counting CT allows better visualization of temporal bone structures in comparison with current generation multi-detector CT. Insights Imaging. 2023 Jul 3;14(1):112. doi: 10.1186/s13244-023-01467-w.
- Benson JC, Campeau NG, Diehn FE, Lane JI, Leng S, Moonis G; ASHNR Research Committee. Photon-Counting CT in the Head and Neck: Current Applications and Future Prospects. AJNR Am J Neuroradiol. 2024 Aug 9;45(8):1000-1005. doi: 10.3174/ajnr.A8265.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 4981
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro laringeo
-
Zeba Ahmad, Ph.D.American Cancer Society, Inc.ReclutamentoCaregiving for CancerStati Uniti
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
Institut Cancerologie de l'OuestAttivo, non reclutanteQualità della vita al lavoro | Professionisti paramedici | Toccare Massaggio | Cancer CenterFrancia
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
Yonsei UniversityNon ancora reclutamentoRAS/BRAF Wild-Type Advanced Cancer MathementCorea, Repubblica di
-
NRG OncologyNational Cancer Institute (NCI)CompletatoCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea del Sud
-
Jonsson Comprehensive Cancer CenterReclutamentoAdenocarcinoma prostatico | Cancro alla prostata in stadio II AJCC v8 | Fase I Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Jonsson Comprehensive Cancer CenterNovartis PharmaceuticalsReclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Second Affiliated Hospital, School of Medicine,...Attivo, non reclutanteElettroacopuntura combinata con paclitaxel legato alla proteina e anticorpo PD-1 per il trattamento di seconda linea di HER2 negativo, PMMR/MSS Advanced Gastric CancerCina
Prove cliniche su Photon Counting Computed Tomography
-
Istituto Ortopedico RizzoliCompletatoDislocazione femoro-rotuleaItalia